25 Sep 2024 — SynBalance reveals Health Canada officially authorizes the functional claim for SynbÆctive Femme, a patented probiotic combination featuring L. plantarum PBS068, L. rhamnosus LRH020 and B. lactis BL050. The probiotic blend is specially formulated to address women’s urogenital health needs.
According to the company, prioritizing women’s urogenital health is essential for preventing conditions such as bacterial vaginosis, which impacts up to 30% of women globally. Focusing on this area of health can improve overall well-being, decrease the risk of chronic diseases and support sustained health, helping women to live more active, comfortable and satisfying lives.
‘We are thrilled that an institution as rigorous as Health Canada has recognized the quality and scientific value of Femme,” says Cristiana Piangiolino, managing director at SynBalance. “This achievement reflects our dedication to developing innovative, science-backed probiotic ingredients.”
“We are looking forward to seeing the first Canadian-licensed formulations in the market in early 2025.”
The company will showcase its ingredients at the upcoming CPHI trade show (October 8–10) in Milan, Italy, at booth #3G17.
Women’s health at the forefront
A long-overlooked area of product and research and development, women’s health space continues to expand. Data from Innova Market Insights suggests a 23% growth in women’s specialty supplements featuring probiotic and prebiotic ingredients from July 2019 to June 2024. L. rhamnosus was the most common probiotic in 34% of these products, while L. plantarum is emerging as the fastest-growing trend. SynbÆctive Femme contains versions of both strains.
SynBalance points out that the product has been extensively studied, with three clinical studies confirming its efficacy in improving urogenital health. One study demonstrated that it successfully colonizes and persists in the vaginal environment, migrating from the intestinal tract.
A second study shows that SynbÆctive Femme significantly reduces bacterial vaginosis recurrence and promotes a healthy vaginal microbiome. Moreover, it showed significant anti-inflammatory effects, an increase in healthy bacteria and improved overall vaginal health in menopausal women after 28 days of supplementation.
Allowed claims
SynBalance highlights that the Health Canada authorization boosts its credibility and visibility in North America and fosters stronger ties with local partners and customers.
The approved health claims include: helps support feminine and digestive health, helps naturally maintain and support feminine health, clinically shown to help support vaginal health and helps maintain healthy vaginal flora.
Health Canada recently authorized similar approvals for Lallemand Health Solutions’ L. plantarum Rosella probiotic strain.